Baxter is a multinational, pharmaceutical and biomedical company operating in more than 100 countries, with over 50,000 employees. In operation for more than 80 years worldwide, and over 40 years in Italy, the company has been helping healthcare professionals and patients by providing them therapies for the treatment of serious and chronic conditions. In 2013, the acquisition of the Swedish company Gambro AB was completed on a global level. On 1 July 2015, Baxter split its business areas, giving life to two global independent companies operating in the field of health. The 'new' Baxter provides a broad portfolio of products, with both hospital and home-based medical and renal therapies.

The Renal division offers products and treatments for patients suffering from kidney diseases. Baxter provides a personalized therapy through a wide range of therapeutic options, available both at home and in hospitals. Its portfolio includes innovative technologies and therapies for peritoneal dialysis, hemodialysis, continuous replacement renal therapy (CRRT).

Its Hospital Products division includes drugs and devices for surgery, anesthesia and parenteral nutrition. Baxter provides sterile intravenous solutions, infusion systems and devices, pharmaceutical compounding services in oncology and a homecare service. As to home-based care, patients are treated at home throughout the care cycle, thanks to a specialized nursing staff. These unique characteristics allow the company to fully respond to the needs of physicians and patients alike.